$8.81+0.25 (+2.92%)
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Kura Oncology, Inc. in the Healthcare sector is trading at $8.81 with a market capitalization of $768M. Wall Street consensus targets $31.17 (12 analysts), implying a +253.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $12.49, remaining 5.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; D...
Kura Oncology’s current analyst price targets remain unchanged, with no revisions in either direction. While there is no new analyst commentary to unpack this time, the lack of adjustments itself can still matter for how you think about risk and reward. In the sections that follow, you will see how to track these kinds of quiet periods in the data so you can stay on top of the evolving narrative around this stock. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO,...
One thing we could say about the analysts on Kura Oncology, Inc. ( NASDAQ:KURA ) - they aren't optimistic, having just...
It's been a good week for Kura Oncology, Inc. ( NASDAQ:KURA ) shareholders, because the company has just released its...
Moby summary of Kura Oncology, Inc.'s Q1 2026 earnings call
Kura Oncology Inc (KURA) reports promising revenue from KOMZIFTI's debut, despite increased R&D and administrative costs impacting net loss.